Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 14 de 14
Filter
Add more filters








Publication year range
1.
J Hosp Infect ; 106(3): 585-593, 2020 Nov.
Article in English | MEDLINE | ID: mdl-32889028

ABSTRACT

BACKGROUND: Heater-cooler units (HCUs) used during cardiopulmonary bypass may become colonized with non-tuberculous mycobacteria (NTM), including Mycobacterium chimaera. Recently, a worldwide investigation conducted in hospitalized infected patients has detected M. chimaera in several Stockert 3T HCUs manufactured by LivaNova. AIM: Microbiological surveillance on Stockert 3T (LivaNova) and Maquet HCU40 (Getinge) devices as well as an evaluation of the efficacy of their recommended decontamination protocols. METHODS: A total of 308 water samples were collected from 29 HCUs: 264 samples were collected from 17 Stockert 3T HCUs and 44 samples from 12 Maquet HCU40 devices. Samples were tested for total viable counts (TVCs) at both 22 and 36°C, Pseudomonas aeruginosa, coliform bacteria, and NTM. The microbiological surveillance began in June 2017 and ran until October 2019. FINDINGS: A total of 308 HCU water samples were analysed, 65.5% of which yielded NTM. The most frequently colonized device with NTM was the Stockert 3T (88.2%), with a frequency of positive samples of 59.5% (157/264). The Maquet HCU40 devices less frequently yielded NTM (33.3%), with a frequency of positive water samples of 13.6% (6/44). Disinfection procedures were effective in reducing TVCs of bacteria with the exception of NTM species. NTM were detected in both pre-disinfection (50.1%) and post-disinfection (55.7%) samples, and no significant association was found between disinfection and NTM results both in Stockert 3T and Maquet HCU40 devices. CONCLUSION: This study suggests that manufacturers' procedures for disinfection are ineffective and/or inadequate. Until effective disinfection protocols become available, the only way to minimize the risk of NTM contamination is to closely monitor the water quality in the HCU, keep it as clean as possible, and treat it like any other biohazardous material.


Subject(s)
Disinfection/standards , Equipment Contamination/prevention & control , Heating/instrumentation , Nontuberculous Mycobacteria/drug effects , Water Microbiology , Cardiac Surgical Procedures/adverse effects , Cardiac Surgical Procedures/instrumentation , Disinfectants/pharmacology , Humans , Italy , Mycobacterium/drug effects , Mycobacterium/genetics , Mycobacterium Infections/prevention & control , Nontuberculous Mycobacteria/genetics
2.
J Hosp Infect ; 104(3): 365-373, 2020 Mar.
Article in English | MEDLINE | ID: mdl-31628958

ABSTRACT

BACKGROUND: Invasive non-tuberculous mycobacteria (NTM) infections are emerging worldwide in patients undergoing open-chest cardiac bypass surgery exposed to contaminated heater-cooler units (HCUs). Although this outbreak has been investigated by culturing bacteria isolated from HCU aerosol and water samples, these conventional methods have low-analytic sensitivity, high rates of sample contamination, and long turnaround time. AIM: To develop a simple and effective method to detect NTM in HCUs by real-time polymerase chain reaction (PCR), with a short laboratory turnaround time and reliable culture results. METHODS: A total of 281 water samples collected from various HCUs at seven Italian hospitals were simultaneously screened for NTM by a propidium monoazide (PMA)-PCR assay and by conventional culture testing. The results were analysed with culture testing as the reference method. FINDINGS: (i) The agreement between culture testing and PMA-PCR was 85.0% with a cycle threshold (CT) cut-off value of <38 vs 80.0% with a CT of <43, with a moderate Cohen's κ-coefficient; (ii) the CT cut-off value of <42 was deemed more suitable for predicting positive specimens; (iii) given the low concentration of target DNA in water samples, the minimum volume to be tested was 1 L. CONCLUSION: The use of PMA-PCR for fast detection of NTM from environmental samples is highly recommended in order to ascertain whether HCUs may represent a potential source of human exposure to NTM. This reliable and simple method reduces laboratory turnaround time compared to conventional methods (one to two days vs eight weeks, respectively), thereby improving control strategies and effective management of HCUs.


Subject(s)
Azides/pharmacology , Equipment Contamination , Mycobacterium/isolation & purification , Propidium/analogs & derivatives , Water Microbiology , Humans , Mycobacterium Infections/prevention & control , Propidium/pharmacology , Real-Time Polymerase Chain Reaction , Time Factors
3.
Ultrason Sonochem ; 19(4): 939-52, 2012 Jul.
Article in English | MEDLINE | ID: mdl-22316613

ABSTRACT

This paper describes theoretical and experimental methods for characterising the performance of a 25 kHz sonochemical reactor (RV-25), which is being developed as a reference facility for studying acoustic cavitation at the National Physical Laboratory (NPL). Field measurements, acquired in different locations inside the sonoreactor, are compared with finite element models at different temperatures, showing that relatively small temperature variations can result in significant changes in the acoustic pressure distribution (and consequent cavitation activity). To improve stability, a deeper insight into the way energy is transferred from the power supply to the acoustic field is presented, leading to criteria - based on modal analysis - to dimension and verify an effective temperature control loop. The simultaneous use of measurements and modelling in this work produced guidelines for the design of multi-frequency cylindrical sonoreactors, also described.


Subject(s)
Sonication/instrumentation , Reference Standards , Sonication/standards , Temperature
4.
J Radiol Prot ; 29(2): 183-200, 2009 Jun.
Article in English | MEDLINE | ID: mdl-19454793

ABSTRACT

We present the results of a neutron shielding design and optimisation study performed to reduce the exposure to radiological doses arising from a 14 MeV pulsed neutron generator (PNG) having a maximum emission strength of 2.0 x 10(8) neutrons s(-1). The source was intended to be used in a new irradiation facility for the realisation of an experiment on acoustical cavitation in liquids. This paper describes in detail how the facility was designed to reduce both neutron and gamma-ray dose rates to acceptable levels, taking into account the ALARP principle in following the steps of optimisation. In particular, this work compares two different methods of optimisation to assess neutron dose rates: the use of analytical methods and the use of Monte Carlo simulations (MCNPX 2.4). The activation of the surrounding materials during operation was estimated using the neutron spectra as input to the FISPACT 3.0 code. The limitations of a first-order analytical model to determine the neutron activation levels are highlighted. The impact that activation has on the choice of the materials to be used inside the laboratory and on the waiting time before anyone can safely enter the room after the neutron source is switched off is also discussed.


Subject(s)
Computer-Aided Design , Facility Design and Construction/methods , Laboratories , Particle Accelerators , Radiation Protection/instrumentation , Research/instrumentation , Equipment Design , Equipment Failure Analysis , Facility Design and Construction/instrumentation , Neutrons , Radiation Protection/methods , Research Design , United Kingdom
5.
J Am Pharm Assoc (Wash) ; 39(1): 50-64; quiz 101-2, 1999.
Article in English | MEDLINE | ID: mdl-9990188

ABSTRACT

OBJECTIVE: To describe the steps pharmacists must complete when seeking compensation from third party payers for pharmaceutical care services. DATA SOURCES: Government publications; professional publications, including manuals and newsletters; authors' personal experience. DATA SYNTHESIS: Pharmacists in increasing numbers are meeting with success in getting reimbursed by third party payers for patient care activities. However, many pharmacists remain reluctant to seek compensation because they do not understand the steps involved. Preparatory steps include obtaining a provider/supplier number, procuring appropriate claim forms, developing data collection and documentation systems, establishing professional fees, creating a marketing plan, and developing an accounting system. To bill for specific patient care services, pharmacists need to collect the patient's insurance information, obtain a statement of medical necessity from the patient's physician, complete the appropriate claim form accurately, and submit the claim with supporting documentation to the insurer. Although many claims from pharmacists are rejected initially, pharmacists who work with third party payers to understand the reasons for denial of payment often receive compensation when claims are resubmitted. CONCLUSION: Pharmacists who follow these guidelines for billing third party payers for pharmaceutical care services should notice an increase in the number of paid claims.


Subject(s)
Insurance, Health, Reimbursement , Pharmaceutical Services/economics , Centers for Medicare and Medicaid Services, U.S. , Documentation/standards , Fees, Pharmaceutical , Humans , Insurance Claim Reporting , Insurance, Pharmaceutical Services , United States
SELECTION OF CITATIONS
SEARCH DETAIL